MA31135B1 - Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt. - Google Patents

Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt.

Info

Publication number
MA31135B1
MA31135B1 MA31763A MA31763A MA31135B1 MA 31135 B1 MA31135 B1 MA 31135B1 MA 31763 A MA31763 A MA 31763A MA 31763 A MA31763 A MA 31763A MA 31135 B1 MA31135 B1 MA 31135B1
Authority
MA
Morocco
Prior art keywords
wnt
diagnosis
treatment
mediated disorders
antagonists
Prior art date
Application number
MA31763A
Other languages
Arabic (ar)
English (en)
Inventor
James A Ernst
Paul Polakis
Bonnee Rubinfeld
Almeida Venita I De
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA31135B1 publication Critical patent/MA31135B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)

Abstract

La présente invention concerne des antagonistes de wnt chimères comprenant un composant de domaine frz dérivé d'une protéine frizzled, une protéine connexe frizzled secrétée ou une protéine ror et un composant d'immunoglobuline fc, et leur utilisation dans le traitement et la détection aux fins de diagnostic d'une signalisation wnt cellulaire et de troubles à médiation wnt, dont le cancer
MA31763A 2006-09-08 2009-04-06 Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt. MA31135B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82506306P 2006-09-08 2006-09-08
US95117507P 2007-07-20 2007-07-20
PCT/US2007/077845 WO2008031009A2 (fr) 2006-09-08 2007-09-07 Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles à médiation wnt

Publications (1)

Publication Number Publication Date
MA31135B1 true MA31135B1 (fr) 2010-02-01

Family

ID=39092004

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31763A MA31135B1 (fr) 2006-09-08 2009-04-06 Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt.

Country Status (19)

Country Link
US (5) US7947277B2 (fr)
EP (1) EP2061495A2 (fr)
JP (1) JP2010504081A (fr)
KR (1) KR20090060334A (fr)
AR (1) AR062709A1 (fr)
AU (1) AU2007292242A1 (fr)
BR (1) BRPI0714751A2 (fr)
CA (1) CA2662041A1 (fr)
CL (1) CL2007002609A1 (fr)
CR (1) CR10699A (fr)
IL (1) IL197240A0 (fr)
MA (1) MA31135B1 (fr)
MX (1) MX2009002522A (fr)
NO (1) NO20091413L (fr)
PE (3) PE20081217A1 (fr)
RU (1) RU2009113023A (fr)
SG (2) SG174101A1 (fr)
TW (1) TW200819463A (fr)
WO (1) WO2008031009A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
AU2006344359B2 (en) 2005-10-31 2013-08-15 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP2009065938A (ja) * 2007-09-14 2009-04-02 Matsumoto Shika Univ タンパク質、破骨細胞分化阻害剤、炎症性骨破壊治療薬、遺伝子、組み替えベクター、及びタンパク質の製造方法
CA2707735A1 (fr) * 2007-12-13 2009-06-18 Gabriela Saborio Proteines de fusion sarp-1 et leurs utilisations
ES2526928T3 (es) 2008-04-30 2015-01-16 The Governing Council Of The University Of Toronto Uso de SFRP-3 en la evaluación de la insuficiencia cardíaca
ES2334092B1 (es) * 2008-07-02 2011-01-24 Proyecto De Biomedicina Cima, S.L. Agentes antiangiogenicos.
WO2010037041A2 (fr) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Agents se liant aux récepteurs frizzled et leurs utilisations
WO2010038756A1 (fr) 2008-09-30 2010-04-08 協和発酵キリン株式会社 COMPOSITION PHARMACEUTIQUE DESTINÉE À TRAITER DES MALADIES DES OS COMPRENANT UNE PROTÉINE COMPRENANT UN DOMAINE EXTRACELLULAIRE RICHE EN CYSTÉINE DE TYPE Frizzled1, Frizzled2 ET Frizzled7
US9316646B2 (en) 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
WO2010132532A1 (fr) 2009-05-15 2010-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps réagissant à la surface des lymphocytes b
US20110189097A1 (en) * 2009-11-09 2011-08-04 Dritan Agalliu Use of WNT inhibitor to inhibit angiogenesis in the CNS
TWI535445B (zh) * 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
JP2013530929A (ja) * 2010-04-01 2013-08-01 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
EP2585098B1 (fr) 2010-06-28 2014-08-27 Five Prime Therapeutics, Inc. Domaines extracellulaires fzd8 et molécules de fusion au domaine extracellulaire fzd8 pour l'utilisation dans le traitement de l'obésité et troubles liés à l'obésité
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
SG189271A1 (en) 2010-10-20 2013-05-31 Genentech Inc Methods and compositions for modulating the wnt pathway
CA2817975C (fr) * 2010-11-16 2020-03-31 Michael Kahn Antagonistes du systeme cbp/catenine destines a promouvoir la division asymetrique des cellules souches somatiques
EP2646469B1 (fr) 2010-12-01 2017-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Anticorps ror1 chimériques lapin/humain
AU2012271413B2 (en) 2011-06-17 2017-07-13 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
JP6121902B2 (ja) 2011-06-21 2017-04-26 協和発酵キリン株式会社 Ｆｒｉｚｚｌｅｄ２の細胞外領域蛋白質のトランケート体を含む蛋白質、および該蛋白質を含有する骨疾患治療用医薬組成物
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
US20130216546A1 (en) * 2012-01-10 2013-08-22 Ngm Biopharmaceuticals, Inc. Methods of Treating Glucose Metabolism Disorders
US20130209473A1 (en) 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
LT2817329T (lt) 2012-02-20 2019-04-10 Swedish Orphan Biovitrum Ab (Publ) Polipeptidai, prisijungiantys prie žmogaus komplemento c5
JP2015536933A (ja) * 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
EP2935335B1 (fr) * 2012-12-19 2020-10-28 Affibody AB Nouveaux polypeptides
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
JP2017501137A (ja) 2013-12-02 2017-01-12 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターに関連する予測バイオマーカーの同定
EP3166627A1 (fr) 2014-07-11 2017-05-17 Genentech, Inc. Inhibition de la voie de signalisation notch
KR101572606B1 (ko) 2014-11-24 2015-11-27 강원대학교산학협력단 Sfrp5 유래의 펩타이드 및 이를 포함하는 피부 미백용 화장료 조성물
WO2016126054A1 (fr) 2015-02-04 2016-08-11 (주)메드팩토 Composition pour prévenir ou traiter un trouble de l'érection comprenant une protéine dkk2 modifiée ou un gène pour celle-ci, et son procédé d'utilisation
CA3014498A1 (fr) * 2016-03-21 2017-09-28 Children's Medical Center Corporation Compositions et methodes pour inhiber la signalisation de wnt
CN108310366A (zh) * 2017-01-15 2018-07-24 复旦大学附属华山医院 重组sfrp5蛋白在制备治疗非酒精性脂肪性肝炎药物中的用途
US20230192846A1 (en) * 2019-11-18 2023-06-22 The Regents Of The University Of California Anti-ror-2 antibodies and methods of use
JP2023503615A (ja) * 2019-11-26 2023-01-31 シーダーズ－サイナイ メディカル センター 循環からミトコンドリアｄｎａ又はゲノムｄｎａを枯渇させることにより疾患及び症状を治療する組成物及び方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039357A1 (fr) * 1996-04-12 1997-10-23 The Board Of Trustees Of The Leland Stanford Junior University COMPOSITIONS A BASE DU RECEPTEUR DE Wnt ET PROCEDES D'UTILISATION DE CELLES-CI
EP0932678B2 (fr) * 1996-09-24 2010-03-10 Genentech, Inc. Famille de genes codant les peptides lies a l'apoptose, peptides ainsi codes et leurs procedes d'utilisation
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP5179689B2 (ja) * 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
AU2001272974A1 (en) 2000-06-21 2002-01-02 Incyte Genomics, Inc. Human receptors
US7413873B2 (en) * 2001-01-30 2008-08-19 The Regents Of The University Of California Method of detection and treatment of colon cancer
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
AU2002308557A1 (en) * 2001-05-01 2002-11-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
WO2003004045A2 (fr) 2001-07-05 2003-01-16 Xenon Genetics, Inc. Procedes permettant d'identifier des agents therapeutiques pour traiter des maladies impliquant des polypeptides wnt et des recepteurs wnt
WO2003009814A2 (fr) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Nouveaux genes, compositions, trousses et methodes d'identification, evaluation, prevention, et traitement du cancer de la prostate
CA2501235A1 (fr) * 2002-10-04 2004-04-22 The Regents Of The University Of California Methodes de traitement du cancer par inhibition de la signalisation de wnt
US7803783B2 (en) * 2002-12-06 2010-09-28 The Board Of Trustees Of The Leland Stanford Junior University Use of WNT inhibitors to augment therapeutic index of chemotherapy
US20040171559A1 (en) * 2002-12-06 2004-09-02 Irving Weissman Protection of stem cells from cytotoxic agents by modulation of beta-catenin signaling pathways
US20050096263A1 (en) * 2003-10-30 2005-05-05 Keay Susan K. Novel antiproliferative factor and methods of use
US7867705B2 (en) * 2004-09-21 2011-01-11 Rhode Island Hospital, A Lifespan-Partner Frizzled proteins and detection and treatment of cancer
WO2006036175A2 (fr) 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Proteines wnt et detection et traitement du cancer
KR101549245B1 (ko) 2004-09-21 2015-09-01 로드아일랜드 하스피털, 에이 라이프스팬 파트너 Ｗｎｔ 단백질 및 암의 검출 및 치료
WO2006055635A2 (fr) 2004-11-15 2006-05-26 Mount Sinai School Of Medicine Of New York University Compositions et methodes de modification de la signalisation autocrine wnt
US7723477B2 (en) * 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth

Also Published As

Publication number Publication date
PE20120806A1 (es) 2012-07-25
US20170349639A1 (en) 2017-12-07
TW200819463A (en) 2008-05-01
WO2008031009A3 (fr) 2009-07-02
US20120141481A1 (en) 2012-06-07
EP2061495A2 (fr) 2009-05-27
WO2008031009A2 (fr) 2008-03-13
CL2007002609A1 (es) 2008-04-18
PE20081217A1 (es) 2008-09-24
JP2010504081A (ja) 2010-02-12
US20080299136A1 (en) 2008-12-04
SG174100A1 (en) 2011-09-29
KR20090060334A (ko) 2009-06-11
PE20120807A1 (es) 2012-07-26
RU2009113023A (ru) 2010-10-20
US7947277B2 (en) 2011-05-24
AU2007292242A1 (en) 2008-03-13
IL197240A0 (en) 2011-08-01
CR10699A (es) 2009-07-10
CA2662041A1 (fr) 2008-03-13
NO20091413L (no) 2009-06-08
US20100266593A1 (en) 2010-10-21
AR062709A1 (es) 2008-11-26
SG174101A1 (en) 2011-09-29
BRPI0714751A2 (pt) 2014-06-24
MX2009002522A (es) 2009-06-19
US20110311534A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
MA31135B1 (fr) Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt.
MA30900B1 (fr) Anticorps d'agonistes anti-notch3 et leur utilisation dans le traitement de maladies liées à notch3
FR21C1004I2 (fr) Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffe
WO2002086443A8 (fr) Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon
WO2008134569A3 (fr) Diagnostic et traitement de la rectocolite hémorragique chez la population portoricaine
MA31156B1 (fr) Modulateurs de partenaires de liaison de la sclerostine pour traiter des troubles lies aux os
MA30962B1 (fr) Anticorps antifacteurs d'humanisés et leurs utilisations.
MA30632B1 (fr) Anticorps humanisé
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
HK1117083A1 (en) Compositions and methods for treatment of eye disorders
NO20072721L (no) Polypeptides that bind BR3 and uses thereof
WO2007149985A3 (fr) Systemès et procédés pour analyser et évaluer la démence et des troubles de type démence.
MA45801B1 (fr) Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine
MA30868B1 (fr) Derives de 2-aminocarbonyl-pyridine
MA30041B1 (fr) Immunoglobulines
Collins et al. Direct immunofluoresence in vasculitic neuropathy: specificity of vascular immune deposits
WO2006099543A3 (fr) Methodes d'evaluation de la toxicite induite par des anticorps
MA30903B1 (fr) Derives de 2 - phenyl-6-minocarbonyl-pyrimidine
MA46814B2 (fr) Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet
ATE415632T1 (de) Verfahren zur diagnose und behandlung von morbus crohn
DE602004024549D1 (de) Diagnose und überwachung von hepatozellulärem karzinom
EP3740761A4 (fr) Diagnostic compagnon pour ains et donépézil pour le traitement de sous-populations spécifiques de patients souffrant de la maladie d'alzheimer
WO2005124358A3 (fr) Diagnostic et traitement de maladies associees a siglec-6
FR2889068B1 (fr) Nouvelles fractions proteiques laitieres et leur utilisation pour la prevention ou le traitement des maladies inflammatoires chroniques
NO20033115D0 (no) Peptid-baserte forbindelser